NFKB1 and Huntington disease: To the best of our knowledge, this is the first study to show that SSCE may attenuate 3-NPA-induced striatal toxicity by regulating various inflammatory cascades (Nrf2, MAPKs, and NF-κB pathways) and may be a potential therapeutic agent for HD-like symptoms.